Home LiteratureArticle Details
PMID: 21092082 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups.

Breast cancer research : BCR ·Vol. 12 ·No. 6 ·2010-00-00 ·Pages R99

Kurian AW, Fish K, Shema SJ, Clarke CA

Abstract

Breast cancer comprises clinically distinct subtypes, but most risk statistics consider breast cancer only as a single entity. To estimate subtype-specific lifetime breast cancer risks, we took advantage of population-based data for which information regarding tumor expression of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu (HER2) was newly available. We included women whose breast cancer was diagnosed in the state of California from 2006 to 2007 and was reported to the National Cancer Institute's Surveillance, Epidemiology and End Results Program (N = 40,936). We calculated absolute lifetime and age-specific probabilities (percent, 95% confidence interval) of developing breast cancer subtypes defined by ER, PR, and HER2 status - luminal (ER and/or PR-positive, HER2-negative), HER2-positive (ER and PR-positive or negative, HER2-positive), and triple-negative (ER-negative, PR-negative, and HER2-negative) - separately for white, black, Hispanic, and Asian women. The luminal breast cancer subtype predominates across racial/ethnic groups, with lifetime risk lowest in Hispanic women (4.60%, 4.41-4.80%) and highest in white women (8.10%, 7.94-8.20%). HER2-positive breast cancer varies less by race (1.56-1.91%). Lifetime risk of triple-negative breast cancer is highest in black women (1.98%, 1.80-2.17%), compared to 0.77% (0.67-0.88%) for Asians, 1.04% (0.96-1.13%) for Hispanics and 1.25% (1.20-1.30%) for whites. Across racial/ethnic groups, nearly half of all luminal breast cancers occur after age 70. These absolute risk estimates may inform health policy and resource planning across diverse populations, and can help patients and physicians weigh the probabilities of developing specific breast cancer subtypes against competing health risks.

MeSH Terms
Asians Biomarkers, Tumor/analysis Blacks Breast Neoplasms/classification,epidemiology,ethnology,metabolism California/epidemiology Female Gene Expression Profiling Hispanic or Latino Humans In Situ Hybridization, Fluorescence Receptor, ErbB-2/analysis Receptors, Estrogen/analysis Receptors, Progesterone/analysis Risk Factors SEER Program Whites
Chemicals
Biomarkers, Tumor Receptors, Estrogen Receptors, Progesterone ERBB2 protein, human Receptor, ErbB-2
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Kurian Allison W
Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305-5405, USA. akurian@stanford.edu
Fish Kari
Shema Sarah J
Clarke Christina A
References (44)
44 references, click to expand
  1. Interval carcinomas in the Malmö Mammographic Screening Trial: radiographic appearance and prognostic considerations.
    AJR Am J Roentgenol. 1992 Aug;159(2):287-94 PMID: 1632342
  2. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer.
    Cancer. 2008 Oct 1;113(7):1521-6 PMID: 18726992
  3. Rethinking screening for breast cancer and prostate cancer.
    JAMA. 2009 Oct 21;302(15):1685-92 PMID: 19843904
  4. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.
    Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7 PMID: 10430922
  5. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
    Breast Cancer Res Treat. 2009 Jan;113(2):357-70 PMID: 18324472
  6. Estimating lifetime and age-conditional probabilities of developing cancer.
    Lifetime Data Anal. 1998;4(2):169-86 PMID: 9658774
  7. Screening for breast cancer: an update for the U.S. Preventive Services Task Force.
    Ann Intern Med. 2009 Nov 17;151(10):727-37, W237-42 PMID: 19920273
  8. Differences in risk factors for breast cancer molecular subtypes in a population-based study.
    Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43 PMID: 17372238
  9. Estimating age conditional probability of developing disease from surveillance data.
    Popul Health Metr. 2004 Jul 27;2(1):6 PMID: 15279675
  10. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    JAMA. 2006 Jun 21;295(23):2727-41 PMID: 16754727
  11. Concordance among gene-expression-based predictors for breast cancer.
    N Engl J Med. 2006 Aug 10;355(6):560-9 PMID: 16899776
  12. Meta-analysis of BRCA1 and BRCA2 penetrance.
    J Clin Oncol. 2007 Apr 10;25(11):1329-33 PMID: 17416853
  13. Repeated observation of breast tumor subtypes in independent gene expression data sets.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 PMID: 12829800
  14. Hospital policy and practice regarding the collection of data on race, ethnicity, and birthplace.
    Am J Public Health. 2003 Oct;93(10):1685-8 PMID: 14534222
  15. On mammography--more agreement than disagreement.
    N Engl J Med. 2009 Dec 24;361(26):2499-501 PMID: 19940286
  16. Epidemiology of basal-like breast cancer.
    Breast Cancer Res Treat. 2008 May;109(1):123-39 PMID: 17578664
  17. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Clin Cancer Res. 2007 Apr 15;13(8):2329-34 PMID: 17438091
  18. Performance of common genetic variants in breast-cancer risk models.
    N Engl J Med. 2010 Mar 18;362(11):986-93 PMID: 20237344
  19. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
    Cancer. 2007 May 1;109(9):1721-8 PMID: 17387718
  20. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.
    PLoS Med. 2010 May 25;7(5):e1000279 PMID: 20520800
  21. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62 PMID: 16288118
  22. Molecular portraits of human breast tumours.
    Nature. 2000 Aug 17;406(6797):747-52 PMID: 10963602
  23. Triple-negative breast cancer: clinical features and patterns of recurrence.
    Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34 PMID: 17671126
  24. Migraine history and breast cancer risk among postmenopausal women.
    J Clin Oncol. 2010 Feb 20;28(6):1005-10 PMID: 20100960
  25. Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer.
    J Clin Oncol. 2009 Nov 10;27(32):5312-8 PMID: 19738113
  26. Triple-negative breast cancers are increased in black women regardless of age or body mass index.
    Breast Cancer Res. 2009;11(2):R18 PMID: 19320967
  27. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.
    J Clin Oncol. 2009 Sep 20;27(27):4515-21 PMID: 19704069
  28. Breast cancer. Clinical practice guidelines in oncology.
    J Natl Compr Canc Netw. 2009 Feb;7(2):122-92 PMID: 19200416
  29. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.
    J Clin Oncol. 2009 Jan 10;27(2):220-6 PMID: 19047281
  30. Age-related crossover in breast cancer incidence rates between black and white ethnic groups.
    J Natl Cancer Inst. 2008 Dec 17;100(24):1804-14 PMID: 19066264
  31. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.
    Breast Cancer Res Treat. 2008 Sep;111(1):27-44 PMID: 17922188
  32. The lifetime risk of developing breast cancer.
    J Natl Cancer Inst. 1993 Jun 2;85(11):892-7 PMID: 8492317
  33. Age-conditional probabilities of developing cancer.
    Stat Med. 2003 Jun 15;22(11):1837-48 PMID: 12754719
  34. Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci.
    JAMA. 2010 Jul 28;304(4):426-34 PMID: 20664043
  35. Assessing women at high risk of breast cancer: a review of risk assessment models.
    J Natl Cancer Inst. 2010 May 19;102(10):680-91 PMID: 20427433
  36. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.
    Breast Cancer Res Treat. 2010 Nov;124(1):133-40 PMID: 20697801
  37. The descriptive epidemiology of second primary breast cancer.
    Epidemiology. 2003 Sep;14(5):552-8 PMID: 14501270
  38. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
    J Clin Oncol. 2008 Sep 10;26(26):4282-8 PMID: 18779615
  39. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    JAMA. 2006 Jun 7;295(21):2492-502 PMID: 16757721
  40. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.
    Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2078-86 PMID: 18664548
  41. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women.
    Breast Cancer Res Treat. 2008 Oct;111(3):405-10 PMID: 18026834
  42. Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer.
    Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):479-85 PMID: 19190139
  43. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
    J Clin Oncol. 2008 Mar 10;26(8):1275-81 PMID: 18250347
  44. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Breast J. 2009 Nov-Dec;15(6):593-602 PMID: 19764994
Article Info
Journal
Breast cancer research : BCR
Abbr.
Breast Cancer Res
ISSN
1465-542X
Published
2010-00-00
Epub
2010-00-19
Pages
R99
Language
English
Region
England
NLM ID
100927353
PMCID
PMC3046442
Subset
IM
Grants
NCCDPHP CDC HHS · 1U58DP00807-01 · United States
NCI NIH HHS · N01-PC-35136 · United States
NCI NIH HHS · N01-PC-35139 · United States
NCI NIH HHS · N01-PC-54404 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com